Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.

Amarnani, Raj; Travis, Simon; Javaid, Muhammad Kassim

Amarnani, Raj; Travis, Simon; Javaid, Muhammad Kassim.

Affiliation

Amarnani R; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford.
Travis S; Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Javaid MK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford.

Rheumatology (Oxford) ; 59(8): 2166-2168, 2020 08 01.

Article in En | MEDLINE | ID: mdl-31930323

Subject(s)

Anemia, Iron-Deficiency/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use; Ferric Compounds/adverse effects; Fibroblast Growth Factors/blood; Hypophosphatemia/drug therapy; Maltose/analogs & derivatives; Osteomalacia/drug therapy; Adult; Anemia, Iron-Deficiency/blood; Ferric Compounds/therapeutic use; Fibroblast Growth Factor-23; Humans; Hypophosphatemia/blood; Hypophosphatemia/chemically induced; Male; Maltose/adverse effects; Maltose/therapeutic use; Osteomalacia/blood; Osteomalacia/chemically induced; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteomalacia / Ferric Compounds / Hypophosphatemia / Anemia, Iron-Deficiency / Antibodies, Monoclonal, Humanized / Fibroblast Growth Factors / Maltose Limits: Adult / Humans / Male Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2020 Type: Article

Fulltext

XML

PubMed Links

Search on Google